BiotechTube
RNAConnect

RNAConnect

San Diego, United States· Est.
rnaconnect.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

RNAConnect is a private, early-stage biotech firm providing advanced enzymatic tools to overcome limitations in conventional RNA analysis. Its core technology, UltraMarathonRT, is a novel group II intron reverse transcriptase engineered for superior processivity, fidelity, and the ability to handle complex RNA structures without heat denaturation. The company operates primarily as a platform/tools provider, selling kits to the research and therapeutic development community, positioning itself as an enabler for the broader RNA therapeutics and multiomics revolution. While currently in an early revenue phase from product sales, its long-term strategy involves empowering more accurate R&D across the biopharma continuum.

RNA TherapeuticsAI / Machine Learning

Technology Platform

UltraMarathonRT (uMRT): A proprietary, engineered group II intron reverse transcriptase with ultra-processivity, intrinsic helicase activity, and high-fidelity for long-read, full-length cDNA synthesis from complex, structured, or low-abundance RNA templates.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The company is positioned to capitalize on the rapid growth in RNA therapeutics, long-read sequencing, and multiomics, where its high-performance enzymes address critical bottlenecks in analyzing complex RNAs.
Key opportunities include becoming the standard tool for quality control in mRNA vaccine and cell/gene therapy manufacturing, and enabling new diagnostic assays requiring high sensitivity.

Risk Factors

Primary risks include intense competition from established life science tools giants, the challenge of driving widespread adoption and protocol change among researchers, and reliance on a single core technology platform.
As a private, early-stage company, scaling manufacturing and achieving profitability are also key financial and operational risks.

Competitive Landscape

RNAConnect competes in the life sciences research tools market against dominant players like Thermo Fisher Scientific, Qiagen, and New England Biolabs, which offer conventional reverse transcriptases. Its differentiation is based on superior technical performance for niche, high-demand applications like long-read sequencing and structured RNA analysis, where it may also face competition from specialized startups and alternative enzyme engineering approaches.

More companies in United States →